Drugs / Avasopasem manganese
Avasopasem manganese
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05412472 | Apr 2019 → Jan 2021 | impaired renal function disease | Galera Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03792971 | Feb 2019 | — | Galera Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03099824 | Oct 2018 → Jan 2020 | — | Galera Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03194139 | Sep → Dec 2017 | — | Galera Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03164109 | Aug → Oct 2017 | — | Galera Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03163173 | Aug → Oct 2017 | — | Galera Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01921426 | Aug 2013 → Jul 2015 | oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Galera Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03340974 | Feb 2018 → Aug 2020 | malignant pancreatic neoplasm | Galera Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04555096 | Sep 2020 → May 2021 | COVID-19 | Galera Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04529850 | Jun 2020 → Mar 2021 | chemotherapy-induced oral mucositis, head and neck cancer | Galera Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04225026 | Dec 2019 → Dec 2021 | esophagitis | Galera Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02508389 | Oct 2015 → Sep 2017 | mucositis | Galera Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03689712 | Oct 2018 → Aug 2021 | mucositis | Galera Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | avasopasem manganese | “cyclic polyamine type (e.g., M40419, today known as GC4419 and avasopasem manganese) have all been shown to positively affect the inflammatory response in lung epithelial cells” PMID 33050459 ↗ Oct 20201“PURPOSE: Avasopasem manganese (GC4419), an investigational selective dismutase mimetic radioprotector, reduced duration, incidence, and severity of severe oral mucositis” PMID 35724774 ↗ Jun 2022 |
| Known as | Avasopasem manganese dichloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297957 ↗ |
| Known as | Avasopasem manganeso | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297957 ↗ |
| Known as | GC4419 | “PURPOSE: Avasopasem manganese (GC4419), an investigational selective dismutase mimetic radioprotector, reduced duration, incidence, and severity of severe oral mucositis” PMID 35724774 ↗ Jun 2022 |
| Known as | M-40419 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297957 ↗ |
| Known as | SC-72325A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297957 ↗ |
| Modality | Other / unclassified | “Avasopasem manganese (AVA or GC4419), a selective superoxide dismutase mimetic” PMID 33980575 ↗ May 2021 |
| Route | Intravenous | “Each dose will be given intravenously over 60 minutes.” NCT01921426 ↗ |